WEBSITE BSE:544644 NSE: CORONA Inc. Year: 2004 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:50
No Notes Added Yet
Corona Remedies Ltd. is an Indian pharmaceutical company primarily focused on branded generic formulations, with a strong presence in chronic therapy segments such as cardiology, diabetology, gastroenterology, pain management, and women’s healthcare. Headquartered in Ahmedabad, the company has built a wide domestic distribution network and a well-recognized portfolio of doctor-prescribed brands in the Indian market. Corona Remedies emphasizes marketing-led growth, brand building, and therapeutic depth rather than bulk exports, making it large...Read More
Corona Remedies Ltd. is an Indian pharmaceutical company primarily focused on branded generic formulations, with a strong presence in chronic therapy segments such as cardiology, diabetology, gastroenterology, pain management, and women’s healthcare. Headquartered in Ahmedabad, the company has built a wide domestic distribution network and a well-recognized portfolio of doctor-prescribed brands in the Indian market. Corona Remedies emphasizes marketing-led growth, brand building, and therapeutic depth rather than bulk exports, making it largely India-focused. Backed by private equity investment, the company continues to expand its product portfolio and strengthen its position in high-growth chronic segments of the Indian pharma industry. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹10560 Cr.
Stock P/E 70.7
P/B 15.1
Current Price ₹1726.6
Book Value ₹ 114.6
Face Value 10
52W High ₹1741
Dividend Yield 0.42%
52W Low ₹ 1337
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2024 | Dec 2024 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|
| Net Sales | 314 | 298 | 361 | 342 |
| Other Income | 2 | 1 | 2 | 2 |
| Total Income | 316 | 298 | 363 | 345 |
| Total Expenditure | 247 | 228 | 283 | 259 |
| Operating Profit | 69 | 70 | 81 | 85 |
| Interest | 3 | 2 | 2 | 2 |
| Depreciation | 9 | 10 | 9 | 9 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -19 |
| Profit Before Tax | 57 | 58 | 70 | 55 |
| Provision for Tax | 14 | 13 | 17 | 14 |
| Profit After Tax | 43 | 45 | 52 | 41 |
| Adjustments | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 43 | 45 | 52 | 41 |
| Adjusted Earnings Per Share | 7 | 7.3 | 8.6 | 6.7 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 884 | 1014 | 1196 | 1315 |
| Other Income | 7 | 6 | 6 | 7 |
| Total Income | 891 | 1021 | 1202 | 1322 |
| Total Expenditure | 756 | 860 | 956 | 1017 |
| Operating Profit | 135 | 161 | 246 | 305 |
| Interest | 4 | 14 | 11 | 9 |
| Depreciation | 20 | 28 | 37 | 37 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -19 |
| Profit Before Tax | 111 | 118 | 199 | 240 |
| Provision for Tax | 26 | 28 | 49 | 58 |
| Profit After Tax | 85 | 91 | 149 | 181 |
| Adjustments | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 85 | 91 | 149 | 181 |
| Adjusted Earnings Per Share | 13.9 | 14.8 | 24.4 | 29.6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 18% | 0% | 0% | 0% |
| Operating Profit CAGR | 53% | 0% | 0% | 0% |
| PAT CAGR | 64% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 28% | 23% | 23% | 23% |
| ROCE Average | 33% | 29% | 29% | 29% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 409 | 480 | 606 |
| Minority's Interest | 0 | 0 | 0 |
| Borrowings | 0 | 67 | 16 |
| Other Non-Current Liabilities | 45 | 59 | 68 |
| Total Current Liabilities | 209 | 269 | 327 |
| Total Liabilities | 663 | 875 | 1017 |
| Fixed Assets | 185 | 384 | 370 |
| Other Non-Current Assets | 115 | 157 | 221 |
| Total Current Assets | 363 | 335 | 426 |
| Total Assets | 663 | 875 | 1017 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 7 | 14 | 3 |
| Cash Flow from Operating Activities | 103 | 157 | 190 |
| Cash Flow from Investing Activities | -50 | -267 | -84 |
| Cash Flow from Financing Activities | -45 | 99 | -107 |
| Net Cash Inflow / Outflow | 8 | -11 | 0 |
| Closing Cash & Cash Equivalent | 14 | 3 | 3 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | 13.89 | 14.8 | 24.43 |
| CEPS(Rs) | 17.17 | 19.42 | 30.51 |
| DPS(Rs) | 2.77 | 3.7 | 7.31 |
| Book NAV/Share(Rs) | 66.8 | 78.55 | 99.14 |
| Core EBITDA Margin(%) | 14.25 | 14.92 | 19.71 |
| EBIT Margin(%) | 12.82 | 12.82 | 17.17 |
| Pre Tax Margin(%) | 12.35 | 11.42 | 16.3 |
| PAT Margin (%) | 9.46 | 8.73 | 12.27 |
| Cash Profit Margin (%) | 11.69 | 11.45 | 15.32 |
| ROA(%) | 12.82 | 11.77 | 15.79 |
| ROE(%) | 20.79 | 20.36 | 27.5 |
| ROCE(%) | 28.03 | 25.93 | 32.59 |
| Receivable days | 35.35 | 32.89 | 32.7 |
| Inventory Days | 42.83 | 35.85 | 34.14 |
| Payable days | 163.28 | 167.89 | 198.94 |
| PER(x) | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | -0.01 | 0.12 | 0.05 |
| EV/Core EBITDA(x) | -0.1 | 0.78 | 0.22 |
| Net Sales Growth(%) | 0 | 14.75 | 17.93 |
| EBIT Growth(%) | 0 | 15.43 | 57.34 |
| PAT Growth(%) | 0 | 6.56 | 65.12 |
| EPS Growth(%) | 0 | 6.56 | 65.12 |
| Debt/Equity(x) | 0.01 | 0.28 | 0.1 |
| Current Ratio(x) | 1.74 | 1.24 | 1.3 |
| Quick Ratio(x) | 1.23 | 0.88 | 0.91 |
| Interest Cover(x) | 26.98 | 9.21 | 19.72 |
| Total Debt/Mcap(x) | 0 | 0 | 0 |
| # | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 69 | 69 | 69 |
| FII | 1.04 | 1.84 | 2.25 |
| DII | 3.6 | 6.76 | 7.02 |
| Public | 26.37 | 22.4 | 21.74 |
| Others | 0 | 0 | 0 |
| Total | 100 | 100 | 100 |
| # | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 4.22 | 4.22 | 4.22 |
| FII | 0.06 | 0.11 | 0.14 |
| DII | 0.22 | 0.41 | 0.43 |
| Public | 1.61 | 1.37 | 1.33 |
| Others | 0 | 0 | 0 |
| Total | 6.12 | 6.12 | 6.12 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
